Single-centre experience and literature review

Clinical and Translational Oncology

Volumn 10, Issue 9, 2008, Pages 560-571

  Carretero, Ana Belén Custodio ^a   Sáenz, José Angel García ^a   Larriba, José Luis González ^a   Bobokova, Jana ^a   Blanco, Antonio Calles ^a   Trancho, Florentino Hernando ^a   Paredes, Beatriz García ^a   Lajusticia, Laura Rodríguez ^a   García, Eduardo Díaz Rubio ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Adjuvant chemotherapy; Non small cell lung cancer; Platinum; Surgical stage; Taxanes

Indexed keywords

EID: 84875031671     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-008-0251-x     Document Type: Article

References (54)

1. Jemal A, Siegel R, Ward E et al (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43-66
2. Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: Globoscan 2000. Int J Cancer 94:153-156
3. Pisani P, Parkin DM, Ferlay J (1993) Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 55:891-903
4. Brambilla E, Travis WD, Colby TV et al (2001) The new World Health Organization classification of lung tumours. Eur Respir J 18:1059-1068
5. Mountain CF (1997) Revisions in the International System for Staging Lung Cancer. Chest 111:1710-1717
6. Manser R, Wright G, Hart D et al (2005) Surgery for early stage non-small cell lung cancer. Cochrane Database Syst Rev Jan 25;1:CD 004699
7. Wright G, Manser RL, Byrnes G et al (2006) Surgery for non-small cell lung cancer: systematic review and meta-analysis of randomised controlled trials. Thorax 61:597-603
8. Van Rens MT, de la Rivière AB, Elbers HR, van Den Bosch JM (2000) Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest 117:374-379
9. Fry WA, Phillips JL, Menck HR (1999) Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer 86:1867-1876
10. Early Breast Cancer Trialists' Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women. Lan cet 339:1-15, 71-85
11. Trimbos JB, Parmar M, Vergote I et al (2003) International Collaborative Ovarian Neoplasm trial 1 and adjuvant chemotherapy in Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 95: 105-112
12. André T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351
13. Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on indi vidual patients from 52 randomised clinical trials. BMJ 311:899-909
14. Keller SM, Adak S, Wagner H et al (2000) A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med 343:1217-1222
15. Scagliotti GV, Fossati R, Torri V et al (2003) Randomized study of adjuvant chemotherapy for completely resected stage I, II or IIIA non-small cell lung cancer. J Natl Cancer Inst 95:1453-1461
16. Waller D, Peake MD, Stephens RJ et al (2004) Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 26:173-182
17. The International Adjuvant Lung Cancer Trial Collaborative Group (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 350:351-360
18. Winton T, Livingston R, Johnson D et al (2005) Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352:2589-2597
19. Douillard JY, Rosell R, de Lena M et al (2006) Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7:719-727
20. Pignon JP, Tribodet H, Scagliotti GV et al (2006) Lung Adjuvant Cisplatin Evaluation(LACE): a pooled analysis of 5 randomized trials including 4584 patients. J Clin Oncol 24:366S [Abstract No 7008 2006 ASCO Annual Meeting
21. Wada H, Hitomi S, Teramatsu T (1996) Adjuvant chemotherapy after complete resection in nonsmall-cell lung cancer. West Japan Study Group for Lung Cancer Surgery. J Clin Oncol 14:1048-1054
22. Endo C, Saito Y, Iwanami H et al (2003) A randomized trial of postoperative UFT therapy in pathological stage I, II non-small cell lung cancer: North-east Japan Study Group for Lung Cancer Surgery. Lung Cancer 40:181-186
23. Nakawava M, Tanaka F, Tsubota N et al West Japan Study Group for Lung Cancer Surgery (2005) A randomized phase III trial f adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG)-the 4th study. Ann Oncol 16:75-80
24. Nakagawa K, Tada H, Akashi A et al (2006) Randomised study of adjuvant chemotherapy for completely resected p-stage I-IIIA non-small cell lung cancer. Br J Cancer 95:817-821
25. Kato H, Ichinose Y, Ohta M et al (2004) A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350:1713-1721
26. Stewart LA, Burdett S, Tierney JF et al (2007) Surgery and adjuvant chemotherapy (CT) compared to surgery alone in non-small cell lung cancer (NSCLC): a meta-analysis using individual patient data (IPD) from randomized clinical trials (RCT). J Clin Oncol 25 [Abstract No 7552 2007 ASCO Annual Meeting
27. Strauss GM, Herndon JE, Maddaus MA et al (2004) Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol 22:7019
28. Strauss GM, Herndon JE, Maddaus MA et al (2006) Adjuvant chemotherapy in stage IB nonsmall cell lung cancer (NSCLC): update of cancer and leukemia Group B protocol 9633. J Clin Oncol 24 [Abstract-No 7007 2006 ASCO Annual Meeting
29. Azzoli CG, Krug LM, Miller VA et al (2007) A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancer. J Thorac Oncol 2: 638-644
30. Feigenberg SJ, Hanlon AL, Langer C et al (2007) A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer. J Thorac Oncol 2:287-292
31. Kreuter M, Vansteenkiste J, Griesinger F et al (2007) Trial on refinement of early stage nonsmall cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol. BMC Cancer 7:77
32. Bradley JD, Paulus R, Graham MV et al (2005) Phase II of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group-RTOG 9705. J Clin Oncol 23:3480-3487
33. Greco FA, Burris HA 3rd, Gray JR et al (2001) Paclitaxel and carboplatin adjuvant chemotherapy alone or with radiotherapy for resected nonsmall cell lung carcinoma: a feasibility study of the Minnie Pearl Cancer Research Network. Cancer 92:2142-2147
34. Kawamura M, Eguchi K, Izumi Y et al (2007) Phase II trial of gemcitabine and docetaxel in patients with completely resected stage IIA-IIIA non-small-cell lung cancer. Cancer Chemother Pharmacol 60:495-501
35. Hamada C, Tanaka F, Ohta M et al (2005) Metaanalysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol 23:4999-5006
36. Pisters KM, Evans WK, Azzoli CG et al (2007) Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol 25:5506
37. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Available at www.nccn.org/professionals/physician-gls/default.asp
38. Feng QF, Wang M, Wang LJ et al (2000) A study of postoperative radiotherapy in patients with non-small-cell lung cancer: a randomized trial. Int J Radiat Oncol Biol Phys 47:925-929
39. Dautzenberg B, Arriagada R, Chammard AB et al (1999) A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma. Groupe d'Etude et de Traitement des Cancers Bronchiques. Cancer 86:265-273
40. Stephens RJ, Irling DJ, Bleehen NM et al (1996) The role of post-operative radiotherapy in nonsmall-cell lung cancer: a multicentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. Medical Research Council Lung Cancer Working Party. Br J Cancer 74:632-639
41. PORT Meta-analysis Trialists Group (1998) Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patients data from nine randomised controlled trials. Lancet 352:257-263
42. Trodella L, Granone P, Valente S et al (2002) Adjuvant radiotherapy in non-small cell lung cancer with pathological stage I: definitive results of a phase III randomized trial. Radiother Oncol 62:11-19
43. Hoang T, Xu R, Schiller JH et al (2005) Clinical model to predict survival in chemonaïve patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol 23:175-183
44. The Lung Cancer Study Group (1987) Postoperative T1N0 non-small cell lung cancer. Squamous versus nonsquamous recurrences. J Thorac Cardiovasc Surg 94:349-354
45. Pairolero PC, Williams DE, Bergstralh EJ et al (1984) Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrence disease. Ann Thorac Surg 38:331-338
46. Mountain CF (1995) New prognostic factors in lung cancer. Biologic prophets of cancer cell aggression. Chest 108:246-254
47. Potti A, Mukherjee S, Petersen R et al (2006) A genomic strategy to refine prognosis in earlystage non-small-cell lung cancer. N Engl J Med 355:570-580
48. Chen H-Y, Yu S-L, Chen CH et al (2007) A fivegene signature and clinical outcome in non-smallcell lung cancer. N Engl J Med 356:11-20
49. Altaha R, Liang X, Yu JJ, Reed E (2004) Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med 14: 959-970
50. Lord RV, Brabender J, Gandara D et al (2002) Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8:2286-2291
51. Olaussen KA, Dunant A, Fouret P et al (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983-991
52. Bepler G, Sharma S, Cantor A et al (2004) RMM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol 22: 1878-1885
53. Zheng Z, Chen T, Li X et al (2007) DNA synthesis and repair genes RMM1 and ERCC1 in lung cancer. N Engl J Med 356:800-808
54. Rosell R, Jassem M, Skrzypski M et al (2007) Increased BRCA1 mRNA: an independent prognostic variable in completely resected chemo-naïve non-small cell lung cancer (NSCLC) patients (p). [Abstract No. 7551 2007 ASCO Annual Meeting]